Practical issues drawn from the implementation of the integrated test for Down syndrome screening into routine clinical practice

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 114, Issue 4, 2007, Pages 493-497

  Weisz, B ^a   Pandya, P ^a   Chitty, L ^a   Jones, P ^a   Huttly, W ^b   Rodeck, C ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Down syndrome; Integrated test; Nuchal translucency; Screening

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL PRACTICE; DOWN SYNDROME; FALSE NEGATIVE RESULT; FEMALE; FETUS; HUMAN; PRENATAL CARE; PRENATAL SCREENING; PRIORITY JOURNAL;

ADOLESCENT; ADULT; DOWN SYNDROME; FEMALE; HUMANS; MASS SCREENING; NUCHAL TRANSLUCENCY MEASUREMENT; PATIENT ACCEPTANCE OF HEALTH CARE; PREGNANCY; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS;

EID: 33847772990     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2007.01238.x     Document Type: Article

References (13)

1. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen 2003;10:56-104.
2. Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, et al. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005;353:2001-11.
3. National Down's Syndrome Screening Programme for England. Antenatal Screening - Working Standards. London: NHS, 2004.
4. National collaborating centre for women's and children's health. Commissioned by the national institute for clinical excellence (NICE). Antenatal Care: Routine Care for the Healthy Pregnant Woman. London: RCOG Press, 2005.
5. Benn P, Wright D, Cuckle H. Practical strategies in contingent sequential screening for Down syndrome. Prenat Diagn 2005;25:645-52.
6. Wright D, Bradbury I, Benn P, Cuckle H, Ritchie K. Contingent screening for Down syndrome is an efficient alternative to non-disclosure sequential screening. Prenat Diagn 2004;24:762-6.
7. Pandya PP, Goldberg H, Walton B, Riddle A, Shelley S, Snijders RJ, et al. The implementation of first-trimester scanning at 10-13 weeks' gestation and the measurement of fetal nuchal translucency thickness in two maternity units. Ultrasound Obstet Gynecol 1995;5:20-5.
8. Alberman E, Huttly W, Hennessy E, McIntosh A. The use of record linkage for auditing the uptake and outcome of prenatal serum screening and prenatal diagnostic tests for Down syndrome. Prenat Diagn 2003;23:801-6.
9. van den BM, Timmermans DR, Kleinveld JH, Garcia E, van Vugt JM, van der WG. Accepting or declining the offer of prenatal screening for congenital defects: test uptake and women's reasons. Prenat Diagn 2005;25:84-90.
10. Rowe RE, Garcia J, Davidson LL. Social and ethnic inequalities in the offer and uptake of prenatal screening and diagnosis in the UK: a systematic review. Public Health 2004;118:177-89.
11. Pajkrt E, van Lith JM, Mol BW, Bleker OP, Bilardo CM. Screening for Down's syndrome by fetal nuchal translucency measurement in a general obstetric population. Ultrasound Obstet Gynecol 1998;12:163-9.
12. Bishop AJ, Marteau TM, Armstrong D, Chitty LS, Longworth L, Buxton MJ, et al. Women and health care professionals' preferences for Down's Syndrome screening tests: a conjoint analysis study. BJOG 2004;111:775-9.
13. Wald NJ, Rodeck C, Hackshaw AK, Rudnicka A. SURUSS in perspective. BJOG 2004;111:521-31.